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Acute liver failure is a condition in which there is rapid
deterioration of liver function, resulting in hepatic encepha-
lopathy and/or coagulopathy.1 In Latin America, complicated
forms of certain tropical infections such as Plasmodium
falciparum malaria, leptospirosis, rickettsial fever, typhoid
fever, viral hepatitis, and rarely dengue, may present as
acute liver failure. Early identification of these infections
is important in reducing morbidity and mortality.2
A 31-year-old previously healthy female presented at our
clinic with a 3-day history of fever, myalgia, bilirubinuria,
arthralgia, and altered mental status. She denied having any
previous history of dengue or malaria. Physical examination
disclosed a diffuse maculopapular rash, asterixis, and jaun-
dice. Ten days prior to her admission she had traveled to
Tolima, Colombia, a hyperendemic area for dengue infection
where an ongoing outbreak due to DEN-2 (dengue virus
serotype 2) was taking place. Laboratory investigations on
admission showed a normal white blood cell (WBC) count and
mild thrombocytopenia; blood chemistries demonstrated a
bilirubin of 8.1 mg/dl, ASTof 2876 UI/l, and ALTof 2120 UI/l.
Her international normalized ratio (INR) was 4.47 with a
prolonged prothrombin time (PT) and a prolonged partial
thromboplastin time (PTT). Thick and thin smears for malaria
and blood cultures were negative. Diagnostic testing for
hepatitis A (IgM), hepatitis B (HBsAg, HBV DNA PCR), hepatitis
C (IgG, HCV RNA PCR), hepatitis E (IgM, IgG), yellow fever
(RNA PCR), Rickettsia spp (IgM/IgG), Epstein—Barr virus,
cytomegalovirus, parvovirus B19 (IgM, IgG), HIV (RNA PCR),
and leptospirosis (ELISA IgM and MAT) were all negative. Her
dengue IgM titers were positive at high titers. There was no
evidence of dengue hemorrhagic fever. A diagnosis of acute
liver failure due to dengue was then made. Despite suppor-
tive efforts, our patient progressed to multiorgan failure and
subsequently died.The clinical spectrum of dengue infections ranges from
asymptomatic infection, to dengue fever (DF), to dengue
hemorrhagic fever (DHF) and dengue shock syndrome
(DHS).2,3 However, sometimes dengue may manifest with
atypical clinical presentations such as acute liver failure.
Indeed, up to 90% of patients with DF may develop mild to
moderateelevationof liver transaminaseswithhigher levelsof
AST.4,5 Liver involvement in DF and DHF has been described in
Asia and the Pacific Islands, and more recently in the Amer-
icas.4—6 However, acute liver failure has rarely been reported
in the setting of DF, andmost of these reports have occurred in
children with DHF and have frequently been associated with
DEN-3 (dengue virus serotype 3) infection.4—6
Dengue virus liver injury may occur due to its ability to
replicate in liver cells leading to hepatocellular injury with
development of Councilman bodies.7,8 In fact, in situ detec-
tion of DNA fragmentation and apoptotic hepatocytes in
association with dengue virus-infected hepatocytes has sug-
gested that hepatocytes are important sites of viral replica-
tion and that dengue virus induces apoptosis in vivo.7
Our case demonstrates that in addition to classic DF and
DHF, testing for dengue should also be pursued among tra-
velers returning from tropical areas endemic for dengue
presenting with acute liver failure.
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E2 antibody in blood donors
I enjoyed the article by Ramezani et al., ‘‘Detection of
hepatitis G virus envelope protein E2 antibody in blood
donors,’’ published in a recent issue of the International
Journal of Infectious Diseases,1 and would like to make some
comments on this article.
Firstly, the authors evaluated hepatitis G virus (HGV)
antibody and ribonucleic acid (RNA) among 478 blood donors
in Tabriz City, but then went on to reflect their results onto
the whole population of Iranian blood donors. Iran is a
country with a population of more than 70 000 000, and a
survey in the northwest of the country, on 478 samples,
cannot be representative of the HGV status for all Iranian
blood donors. The pattern of prevalence of hepatitis G may
well be different in the various other regions of Iran. For
example, Gharebaghian et al. showed the hepatitis G pre-
valence in Tehran, the capital of Iran, to be 4.2% among 330
blood donors,2 a higher prevalence value than that deter-
mined by Ramezani et al. The current prevalence of virus in
other parts of the country remains to be elucidated, and then
a meta-analysis will determine the countrywide pattern.
Secondly, in liver function tests, the mean levels of ALTand
ASTwere cited for both groups — thosewith positive results forHGV and those with negative results for HGV; however, no
reference rangeswere given, whichmakes the description and
interpretation of the results somehow confusing.
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Dear Dr Cameron
Thank you for sending me the letter from H. Mansouri-
torghabeh concerning my article entitled ‘‘Detection of
hepatitis G virus envelope protein E2 antibody in blood
donors,’’ published in the International Journal of Infectious
Diseases.In reply to the first point made, because Tabriz City is not
well known to scholars around the world, we used ‘Iran’ in
the ‘Aims’ section to give readers an immediate understand-
ing of the place of study; however in the ‘Patients and
methods’ section it was explained that the study took place
in Tabriz City. This policy is common inmany papers published
in international journals.1—5 Also, we did not reflect our
results onto all Iranian blood donors. As mentioned in the
‘Discussion’ section, ‘‘We have shown a low frequency of
